Porcine reproductive and respiratory syndrome (PRRS) virus vaccine (Virus PRRSV, kmen VP-046 BIS) - etsinnän tulokset

Euroopan unioni - italia - EMA (European Medicines Agency)

suvaxyn circo+mh rtu

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inattivato virali e batterici inattivati vaccini - pigs - per l'immunizzazione attiva dei suini a partire da 3 settimane di età contro il circovirus suino di tipo 2 (pcv2) per ridurre la carica virale nel sangue e nei tessuti linfoidi e spargimento fecale causati dall'infezione da pcv2. per l'immunizzazione attiva dei suini di età superiore a 3 settimane contro mycoplasma hyopneumoniae per ridurre le lesioni polmonari causate dall'infezione con m. hyopneumoniae.

Euroopan unioni - italia - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologici per suidi - suini da ingrasso) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.